Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
39.57 USD +4.08% Intraday chart for Ultragenyx Pharmaceutical Inc. +1.34% -17.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday MT
Ultragenyx Pharmaceutical Prices $350 Million Offering MT
Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025 MT
Ultragenyx Pharmaceutical Launches Equity Offering MT
Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment DJ
Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate MT
Sector Update: Health Care Stocks Rise Premarket Wednesday MT
Sector Update: Health Care MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM
Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56 MT
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating MT
Stifel Adjusts Price Target on Ultragenyx Pharmaceutical to $127 From $124, Maintains Buy Rating MT
Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating MT
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia CI
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating MT
Chart Ultragenyx Pharmaceutical Inc.
More charts
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
39.6 USD
Average target price
90.05 USD
Spread / Average Target
+127.39%
Consensus
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. News Ultragenyx Pharmaceutical Inc.
  5. RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward